Key facts
- This page summarizes Peter A. Thompson's Form 4 filing for Edgewise Therapeutics, Inc. (EWTX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 20 May 2022, 16:32.
Peter A. Thompson - 18 May 2022 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- EWTX
- Reported as of
- 18 May 2022
- Net transaction value
- +$994,980
- SEC form
- 4
- Accepted by SEC
- 20 May 2022, 16:32:15 UTC
- Prior SEC filing
- 04 Jan 2022
- Next SEC filing
- 13 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Peter A. Thompson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Peter A. Thompson filed Form 4 for Edgewise Therapeutics, Inc. (EWTX) on 20 May 2022.
Change
- Previous filing in this sequence was filed on 04 Jan 2022.
- Current net transaction value: +$994,980.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EWTX
transaction
Common Stock
Purchase
- Transaction value
- $994,980
- Shares
- +138,000
- Change %
- +1%
- Price
- $7.21
- Shares after
- 13,497,456
- Date
- 18 May 2022
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F4
EWTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 319,599
- Date
- 18 May 2022
- Ownership
- See Footnotes
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
These shares of the Issuer's common stock ("Shares") were purchased in multiple transactions at prices ranging from $7.04 to $7.24. The price reported reflects the weighted average purchase price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the ranges set forth in this footnote.
Footnote F2
The Shares are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. The Reporting Person is a member of OrbiMed Advisors. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VI.
Footnote F3
The Shares are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by Genesis Master Fund.
Footnote F4
Each of the Reporting Person, GP VI, OrbiMed Advisors, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. OrbiMed Advisors has designated the Reporting Person, a member of of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Person, GP VI, OrbiMed Advisors, or Genesis GP is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.